<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117311</url>
  </required_header>
  <id_info>
    <org_study_id>09-008825</org_study_id>
    <secondary_id>R01DK082396</secondary_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01117311</nct_id>
  </id_info>
  <brief_title>Vagal Nerve Stimulation and Glucose Metabolism</brief_title>
  <official_title>The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this application is to determine the mechanism(s) by which common
      bariatric surgical procedures alter carbohydrate metabolism. The study proposed will examine
      the effect of vagal nerve stimulation on insulin secretion and action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this application is to determine the mechanism(s) by which common
      bariatric surgical procedures alter carbohydrate metabolism. Very often, resolution of
      diabetes occurs in the early post-operative period prior to the development of significant
      weight loss. It has been suggested that bariatric surgery alters insulin action but few
      studies have examined insulin secretion or postprandial glucose fluxes in such patients. At
      the present time, little is known about how the various bariatric surgical procedures alter
      glucose homeostasis. It is essential that the effect of bariatric surgery and meal size on
      these parameters be understood and accurately measured. Enteroendocrine secretion is affected
      by the rate of intestinal delivery of calories and may also be modulated by the enteric
      nervous system and the rate of direct delivery of nutrients to enteroendocrine cells. Direct
      measurement of intestinal transit is also an important part of understanding how bariatric
      surgery alters intestinal secretion of hormones that may alter glucose metabolism. The Oral
      and C-peptide Minimal Models when applied to C-peptide, glucose and insulin concentrations
      after ingestion of a standard labeled mixed meal can accurately measure insulin secretion and
      action. Subsequently, the disposition index provides a measurement of the appropriateness of
      insulin secretion for the prevailing insulin action. When coupled with established
      triple-tracer methodology, a mixed meal can be used to measure fasting and postprandial
      glucose fluxes. Though the vagal trunks are preserved during bariatric surgery, gastric
      transection during the formation of a gastric pouch for Roux-en-Y gastric bypass (RYGB), or
      during the sleeve gastrectomy for the duodenal switch procedure, may denervate post-gastric
      organs including the pancreas and intestine. Reversible vagal block results in weight loss,
      decreased caloric intake, earlier satiation and reduced hunger. The effect of this form of
      vagal denervation on glycemic control is unclear. There is evidence that hepatic
      parasympathetic input regulates insulin action in rodents. Vagal afferents are also important
      in hepatoportal glucose sensing.

      Subjects enrolled into the study would be on stable Vagal Nerve Stimulation Blocker (VNB)
      intervention in excess of 12 months, having taken part in prior observational study examining
      the long-term effects of vagal inhibition. All subjects will be studied three times after
      using a mixed meal. Participants will be admitted to the Mayo Clinic Clinical Research Unit
      at 17.00 hours the evening before the study. Following ingestion of a standardized low
      calorie mixed meal (400 Kcal: 55% carbohydrate, 30% fat, and 15% protein) subjects will fast
      overnight. During the experiment subjects will undergo a mixed meal study as outlined below
      (Lead-in Mixed Meal 1). On the day after study, subjects will be randomized to one of 2
      interventions: either discontinue use of the VNB or continue its use. Subjects will then be
      restudied (Mixed Meal 2) the day after admission to the Clinical Research Unit at 17.00 hours
      on the 13th day after randomization. To determine the metabolic effects, if any, of starting
      VNB therapy, on the day after study, VNB use will be resumed or discontinued depending on
      prior activation or inactivation. Subjects will then be restudied (Mixed Meal 3) the day
      after admission to the Clinical Research Unit at 17.00 hours on the 13th day after completion
      of Mixed Meal 2. Following completion of the study, VNB use will be resumed in all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>baseline, 2 weeks</time_frame>
    <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric Emptying Half-time</measure>
    <time_frame>approximately 2 hours after radiolabeled meal is ingested</time_frame>
    <description>Gastric emptying half time is the time for half of the ingested solids or liquids to leave the stomach.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Obesity</condition>
  <condition>Gastric Emptying</condition>
  <arm_group>
    <arm_group_label>VNB off first, then VNB on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VNB on first, then VNB off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNB on</intervention_name>
    <description>The implanted Vagal Nerve Blocker will be on at the time of study.</description>
    <arm_group_label>VNB off first, then VNB on</arm_group_label>
    <arm_group_label>VNB on first, then VNB off</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VNB off</intervention_name>
    <description>The implanted Vagal Nerve Blocker will be off at the time of study.</description>
    <arm_group_label>VNB off first, then VNB on</arm_group_label>
    <arm_group_label>VNB on first, then VNB off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Previous Implantation of a Vagal Nerve Stimulator for obesity as part of a prior study
        examining the effect of vagal nerve stimulator on obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <results_first_submitted>August 21, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2014</results_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vagus</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Obesity</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects will be recruited out of the study population for a previous multi-center observational study examining the long-term effects of vagal stimulation. In this previous study the Vagal Nerve Blocker (VNB) was implanted.</recruitment_details>
      <pre_assignment_details>9 subjects were screened and enrolled, but 2 subjects did not return after the screening visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>VNB Off First, Then VNB on</title>
          <description>Subjects assigned to this reporting group had the vagal nerve blocker (VNB) off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).</description>
        </group>
        <group group_id="P2">
          <title>VNB on First, Then VNB Off</title>
          <description>Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Lead-in Mixed Meal 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention - Mixed Meal 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention - Mixed Meal 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes groups randomized to have the VNB off first and the VNB on first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disposition Index</title>
        <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
        <time_frame>baseline, 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VNB on</title>
            <description>The implanted Vagal Nerve Blocker will be on at the time of study.</description>
          </group>
          <group group_id="O2">
            <title>VNB Off</title>
            <description>The implanted Vagal Nerve Blocker will be off at the time of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Index</title>
          <description>Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.</description>
          <units>10^-14dl/kg/min^2 per pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703" spread="240"/>
                    <measurement group_id="O2" value="532" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastric Emptying Half-time</title>
        <description>Gastric emptying half time is the time for half of the ingested solids or liquids to leave the stomach.</description>
        <time_frame>approximately 2 hours after radiolabeled meal is ingested</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VNB on</title>
            <description>The implanted Vagal Nerve Blocker will be on at the time of study.</description>
          </group>
          <group group_id="O2">
            <title>VNB Off</title>
            <description>The implanted Vagal Nerve Blocker will be off at the time of study.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Emptying Half-time</title>
          <description>Gastric emptying half time is the time for half of the ingested solids or liquids to leave the stomach.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" spread="17"/>
                    <measurement group_id="O2" value="160" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VNB Off</title>
          <description>The implanted Vagal Nerve Blocker will be off at the time of study.</description>
        </group>
        <group group_id="E2">
          <title>VNB on</title>
          <description>The implanted Vagal Nerve Blocker will be on at the time of study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adrian Vella</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-3289</phone>
      <email>vella.adrian@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

